Positive Top-Line Results For Denosumab Treatment Of Bone Loss In Men With Non-Metastatic Prostate Cancer Undergoing Androgen Deprivation Therapy
Amgen (NASDAQ: AMGN) announced findings from a three-year pivotal Phase 3 placebo-controlled trial evaluating denosumab in the treatment of bone loss in men undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer.
More: continued here
Filed under: Prostate on July 16th, 2008